Silence Therapeutics plc
SLNCF
$0.95
$0.451490.53%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 159.17% | -236.52% | -50.79% | 80.80% | -8.10% |
| Total Depreciation and Amortization | 6.39% | -5.43% | 1.62% | -6.45% | -14.98% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -341.01% | 1,759.85% | -79.85% | 7.12% | -26.46% |
| Change in Net Operating Assets | -1,360.00% | -86.25% | 248.06% | -125.10% | 70.23% |
| Cash from Operations | -91.10% | -314.66% | 67.56% | -2.23% | 8.21% |
| Capital Expenditure | -- | -152.17% | -2,323.68% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 5,537.60% | -243.32% | 113.16% | -26,398.88% | 94.05% |
| Cash from Investing | 5,532.35% | -243.70% | 111.73% | -31,949.74% | 94.05% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 9.53% | 0.00% | -185.29% | -- | 313.97% |
| Issuance of Common Stock | -- | -50.31% | -70.67% | 167,226.87% | 9,329.02% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 898.37% | 52.37% | -- | -- | -- |
| Cash from Financing | -88.85% | -49.02% | -73.19% | 579,382.25% | 24,138.49% |
| Foreign Exchange rate Adjustments | 1,210.72% | -494.10% | 70.59% | 97.83% | 107.82% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,757.27% | -267.92% | 78.83% | 862.39% | 93.78% |